Sugi Predict

Sugi Predict / Targets / RCE1

RCE1

CAAX prenyl protease 2 · Q9Y256 · RCE1 on Sugi Atlas →

33,366 patent compounds predicted against RCE1, 23,445 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL588919 SCHEMBL588919 0.43 5/20
SCHEMBL234836 SCHEMBL234836 0.61 2/20
SCHEMBL258816 SCHEMBL258816 0.60 2/20
SCHEMBL236627 SCHEMBL236627 0.60 2/20
SCHEMBL396957 SCHEMBL396957 0.60 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL259782) 0.59 2/20
SCHEMBL265109 SCHEMBL265109 0.59 2/20
SCHEMBL168479 SCHEMBL168479 0.57 2/20
SCHEMBL204885 SCHEMBL204885 0.52 2/20
SCHEMBL329215 SCHEMBL329215 0.51 2/20
SCHEMBL222833 SCHEMBL222833 0.42 2/20
SCHEMBL224317 SCHEMBL224317 0.41 2/20
SCHEMBL107442 SCHEMBL107442 1.00 1/20
Flunarizine Flunarizine (SCHEMBL120168) 1.00 1/20
Flunarizine Flunarizine (SCHEMBL120169) 1.00 1/20
SCHEMBL167452 SCHEMBL167452 1.00 1/20
SCHEMBL396671 SCHEMBL396671 1.00 1/20
Levofloxacin Anhydrous Levofloxacin Anhydrous (SCHEMBL15397) 0.98 1/20
Ofloxacin Ofloxacin (SCHEMBL24373) 0.98 1/20
Levofloxacin Anhydrous Levofloxacin Anhydrous (SCHEMBL515263) 0.98 1/20

Clinical trials — most relevant to RCE1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer PHASE3COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma PHASE1/PHASE2RECRUITING
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) PHASE2COMPLETED
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC PHASE2COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer PHASE2COMPLETED
A Prevention Trial in Subjects at High Risk for Breast Cancer PHASE2COMPLETED
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC PHASE2COMPLETED
Study of the Mechanisms of Asthma PHASE1COMPLETED
A Study of the Genetic Analysis of Brain Disorders nanCOMPLETED
Role of Genetic Factors in the Development of Lung Disease nanRECRUITING
Tecfidera Diffusion Tensor Imaging nanCOMPLETED
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD) nanCOMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
Investigation of Copy Number Variations and Genetic Variants in POI nanRECRUITING
Inflammatory Genomics in Human Carotid Artery Disease nanCOMPLETED
PCD New Gene Discovery nanCOMPLETED
Accelerated Aging, HIV Infection, Antiretroviral Therapies nanCOMPLETED
Identification of an Asthma Susceptibility Gene on 3P nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
LRP1 and Colon Cancer nanUNKNOWN
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease nanRECRUITING
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
NCF Gene & TNFSF4 in SLE Patients nanUNKNOWN
Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC) nanUNKNOWN
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a RCE1 binder may also engage these)

ProteinNameSimilarity
A6H7A0 — 0.996 A6H7A0 →
P57791 — 0.993 P57791 →
B0BMW8 — 0.980 B0BMW8 →
B1MTH4 — 0.943 B1MTH4 →
B0KWE9 — 0.939 B0KWE9 →
Q86YN1 — 0.936 Q86YN1 →
B2KI79 — 0.936 B2KI79 →
Q9JMF7 — 0.932 Q9JMF7 →
B0CM95 — 0.931 B0CM95 →
O43688 — 0.930 O43688 →
Q9H6U8 — 0.926 Q9H6U8 →
Q4V899 — 0.920 Q4V899 →
Q8VDI9 — 0.919 Q8VDI9 →
A1A5C7 — 0.919 A1A5C7 →
P52875 — 0.919 P52875 →
Q2HJ61 — 0.918 Q2HJ61 →
TECR Very-long-chain enoyl-CoA reductase 0.918 landscape →
Q3ZCD7 — 0.914 Q3ZCD7 →
TMEM165 Putative divalent cation/proton antiporter TMEM165 0.911 landscape →
Q66H54 — 0.911 Q66H54 →
Q91ZH7 — 0.911 Q91ZH7 →
Q8K593 — 0.911 Q8K593 →
Q3UHH2 — 0.911 Q3UHH2 →
Q96H72 — 0.911 Q96H72 →
Q9DAX2 — 0.911 Q9DAX2 →
Q9QZG1 — 0.910 Q9QZG1 →
Q5R6I6 — 0.908 Q5R6I6 →
Q9UNW1 — 0.907 Q9UNW1 →
GABBR1 Gamma-aminobutyric acid type B receptor subunit 1 0.906 landscape →
Q8R4D1 — 0.905 Q8R4D1 →